uniQure (QURE) Expected to Announce Earnings on Thursday

uniQure (NASDAQ:QURE) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.93) per share and revenue of $4.8350 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:00 AM ET.

uniQure Stock Performance

Shares of uniQure stock opened at $24.03 on Wednesday. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock’s fifty day moving average is $23.72 and its two-hundred day moving average is $29.70. uniQure has a 52 week low of $7.76 and a 52 week high of $71.50. The company has a market capitalization of $1.50 billion, a PE ratio of -5.47 and a beta of 0.66.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Scheduled catalyst — uniQure will report Q4 and full‑year 2025 results before the market opens on March 2, 2026 and host a conference call; this gives investors a near‑term event to reassess revenue, expenses and guidance. uniQure to Announce 2025 Financial Results
• Neutral Sentiment: Analyst initiation — Wolfe Research initiated coverage of uniQure with a “peer perform” (market/sector‑perform) rating, which is neutral and unlikely to provide a strong near‑term positive catalyst. Wolfe Research initiates coverage
• Negative Sentiment: Multiple law firms have filed or are soliciting lead plaintiffs for securities class actions covering the September 24–October 31, 2025 period; increased litigation risk typically depresses sentiment and can pressure the stock. Example notices from Kessler Topaz and others were published today. QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP
• Negative Sentiment: Additional plaintiff‑firm solicitations/press releases (Rosen, Pomerantz, Faruqi & Faruqi, Schall, Berger Montague, Gross, Levi & Korsinsky, DJS, etc.) amplify legal headlines and may deter institutional buyers until legal exposure is clearer. ROSEN encourages investors to secure counsel
• Negative Sentiment: The volume of notices and the April 13, 2026 lead‑plaintiff deadline being highlighted across firms creates headline risk; even without merits assessed, investor uncertainty from potential settlements, legal costs or management distraction can weigh on share price. Pomerantz investor alert

Insider Activity

In other news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the transaction, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. The trade was a 44.19% decrease in their position. The SEC filing for this sale provides additional information. 4.79% of the stock is owned by insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Ensign Peak Advisors Inc increased its stake in uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new stake in shares of uniQure during the third quarter valued at $50,000. Knott David M Jr raised its stake in uniQure by 100.0% in the 4th quarter. Knott David M Jr now owns 4,000 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 2,000 shares during the last quarter. Smartleaf Asset Management LLC purchased a new position in uniQure in the 4th quarter worth $48,000. Finally, Deutsche Bank AG lifted its position in uniQure by 98.3% during the 4th quarter. Deutsche Bank AG now owns 4,621 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 2,291 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

QURE has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. Wells Fargo & Company decreased their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th. Mizuho reduced their price objective on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, December 8th. Chardan Capital reiterated a “buy” rating and issued a $53.00 target price on shares of uniQure in a report on Thursday, December 4th. Finally, Barclays began coverage on uniQure in a research note on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.33.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.